Page 14 - Lupin

US sales pressure hurts Lupin again

Growth in other geographies points to a better second half

Lupin Q2 profit down 31% at Rs 455 cr, but slightly above consensus

The drugmaker profit came in at Rs 455 cr for the quarter ended Sept 30, compared with Rs 662 cr a year earlier

Lupin surges 7% post September quarter earnings

The stock has moved higher by 7% to Rs 1,074 after the company reported a consolidated net profit of Rs 455 crore in Q2FY18

Lupin gets US FDA nod for carbidopa tablets to treat Parkinson's disease

Carbidopa tablets, 25 mg had annual sales of approximately $21.9 million in the US

Lupin: Price erosion still a key concern

Recent acquisition & large product pipeline long-term growth drivers; price erosion in US to weigh on earnings

Lupin buys Symbiomix Therapeutics for $150 mn to boost women's health biz

US market contributes around 45% of Lupin's revenue and this is the drug maker's second big acquisition in US in the last 15 months

Lupin gains 3% on USFDA approval for generic Corgard tablets

The company has received final approval from the US health regulator to market generic Nadolol tablets, used for treatment of hypertension, in the American market.

Lupin appoints Jim Loerop to drive M&A, business development strategy

Loerop will hold the position of chief corporate development officer

Lupin taps external funding for R&D of biosimilars in FY18

Lupin will file biosimilar Etanercept in Europe and Japan in FY 2018 and has tied up with a financial company to fund research and development cost of the drug.Biosimilars are copies of innovative biologic drugs and are made from living cells. Lupin is partnering with an another firm for drug development given the high cost and risks in the process.Etanercept is indicated for treatment of rheumatoid arthritis and is a copy of Amgen's innovative drug Enbrel.At an investor conference in Mumbai last week Lupin's managing director Nilesh Gupta said the company was on track to file Etanercept in Europe and Japan in the current fiscal and is developing a pipeline of select biosimilar drugs. Gupta said that the company is actively partnering for first few products and is targeting a total market size of $ 19 billion.In 2014 Lupin tied up with drug maker Yoshido to help in clinical trials and commercialisation of biosimilars in Japanese market. But the company has been slow to hit the ...

Lupin faces Hurricane Irma impact

Drug maker moves 60 staff from Florida as storm hits state

Lupin eyes speciality businesses in US

Speciality assets are branded businesses for niche therapies that require sales force in the US

Lupin receives USFDA approval for generic anti-inflammatory ointment

Lupin shares on Tuesday ended 1.36 per cent down at Rs 1,018 apiece on BSE

Lupin recalls 12,480 bottles of anti-depressant drug from US

On account of failed dissolution specifications from the US market

Lupin spends big on quality control as US FDA ups scrutiny on Indian pharma

Employees are often videotaped to ensure they follow standard operating procedure

Lupin plans to consolidate generic products

Drug major Lupin is devising plans to consolidate its generic portfolio across key geographies, including the US, with a focus on expansion of complex and specialty products. The Mumbai-based company may look at acquisitions, besides enhanced investment in research and development (R&D), to achieve desired results. "Moving forward, we will consolidate on our generic portfolio while focusing on complex generics and speciality products," Lupin Vice-Chairman Kamal K Sharma said in his address to shareholders in the company's Annual Report for 2016-17. The drugmaker expects to tackle this challenge with appropriate acquisitions, calibrated investments in R&D, supported by right skill sets, he added. "This would enable us to enhance the quality of our business and transcend from the existing paradigm towards new horizons," Sharma said. Elaborating, Lupin MD Nilesh Gupta and CEO Vinita Gupta said the company will consolidate on the generic position across ...

Lupin's 4.5% rise pushes Nifty Pharma index up by 1.5%

Nifty Pharma gained over 1.5% today, making it the top performing index among other sectora

Lupin rebounds 5% from 52-week low on drug launch

The stock up 4% to Rs 1,086, bouncing back 5% from 52-wk low of Rs 1,036 hit in intra-day trade

Dr Reddy's slips to 4th spot in sales revenue as Lupin, Aurobindo race past

Lupin wins second spot with 24% growth in consolidated revenues at Rs 17,494 cr

Centrum maintains buy rating on Lupin; sets target at Rs 1300

Lupin is the market leader in 45 of the 139 products in the US' generic market

Weak US sales pull down Lupin show

Operating performance in the March quarter also impacted by one-offs